No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease

Abstract

Abstract. Introduction: Cardiovascular disease (CVD) accounts as a major cause of mortality among patients with nonalcoholic fatty liver disease (NAFLD). Resveratrol, a natural polyphenol compound, is known for its antioxidant and antiatherogenic properties and is purported to be beneficial in decreasing CVD risk factors in NAFLD patients. Objectives: This study aimed to investigate the effects of resveratrol on atherogenic risk factors in patients with NAFLD. Methods: This randomized, double-blind, placebo-controlled clinical trial was performed on 50 patients with NAFLD aged 20-60 years. Subjects were randomly assigned to receive a daily dose of 600 mg resveratrol (n = 25) or placebo (n = 25) for 12 wk. Serum liver enzymes, lipid profile and atherogenic indices, blood pressure and anthropometric values were assessed pre and post-treatment. Results: Resveratrol supplementation reduced body weight (from 88.75 ± 11.41 to 87.54 ± 11.18 kg, P = 0.005) and BMI (from 31.00 ± 3.16 to 30.60 ± 3.26 kg/m², P = 0.01) significantly compared to the placebo group. A significant reduction in waist circumference was observed within resveratrol group (from 102.70 ± 7.68 to 101.39 ± 7.62 cm, P = 0.02). There were no significant changes in lipid profile (ox-LDL, ApoA1 and ApoB), serum atherogenic indices (LDL-C/HDL-C, ApoB/ApoA1, ox-LDL/ApoB, LDL-C/ox-LDL and AIP), liver enzymes (AST, ALT, ALP and GGT), hip circumference, waist-to-hip ratio and blood pressure in either group (P > 0.05 for all). Conclusion: These findings indicated that resveratrol supplementation in dose and duration used in this study did not affect most of the CVD risk factors in NAFLD patients. Further studies are warranted to explain more effects of resveratrol on CVD complications of NAFLD. Registration ID in IRCT: IRCT201511233664N16

Autophagy in Hepatic Steatosis: A Structured Review

“…The similar contributions of SIRT1 activation in different models suggest a common point of intervention in steatosis development and subsequent resolution. However, some clinical trials did not observe significant reduction of steatosis upon 12 weeks of treatment (Kantartzis et al, 2018;Farzin et al, 2020), a finding that is still under debate regarding the effects of overdosage and treatment length (Fogacci et al, 2018).…”

Astragaloside IV Alleviates Liver Inflammation, Oxidative Stress and Apoptosis to Protect Against Experimental Non-Alcoholic Fatty Liver Disease

“…56 Cardiovascular complications are the main cause of death in NAFLD, recently studies have exposed that resveratrol can reduce BMI and waist circumference in patients with NAFLD, but blood lipids, serum atherosclerosis index, liver enzymes and blood pressure have not changed significantly. 57 Our research illustrations that ASIV can reduce blood lipids and body weight in mice. In follow-up studies, we can further pay attention to the role of ASIV in the complications of NAFLD.…”

Natural Polyphenols in Metabolic Syndrome: Protective Mechanisms and Clinical Applications

“…However, an invalid prescription has been reported in T2D patients, which is due to the complexity of human genetics and other factors [ 42 ]. In addition, the effects of resveratrol on NAFLD progression are more complex [ 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 ], which means that the application of resveratrol for conversion needs to be further evaluated.…”

“…For example, curcumin and silybin both improved NAFLD in humans at different doses without significant gender bias [ 33 , 34 , 35 , 64 , 65 , 66 , 248 ]. However, the effects of resveratrol on patients with NAFLD are controversial [ 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 ]. Among them, resveratrol had no therapeutic effect on NAFLD patients at a low dose (150 mg/day) [ 44 ].…”

“…Among them, resveratrol had no therapeutic effect on NAFLD patients at a low dose (150 mg/day) [ 44 ]. In contrast, at a dose of 300~600 mg/day, most of the studies showed that resveratrol has a good therapeutic effect, including but not limited to the loss of BS, decreased serum hepatic enzymes and lipid content, improved inflammatory signals, and relieved hepatic lipid accumulation [ 45 , 46 , 47 , 48 , 50 ]. However, it does not change the redox state in vivo [ 49 ].…”